Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
July 23 2014 - 4:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 17, 2014
QLT Inc.
(Exact Name of
Registrant as specified in its charter)
|
|
|
|
|
British Columbia, Canada
|
|
000-17082
|
|
N/A
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
887 Great Northern Way, Suite 250, Vancouver, B.C.
Canada, V5T 4T5
(Address
of principal executive offices)
Registrants telephone number, including area code: (604) 707-7000
Not Applicable
(Registrants name or former address, if change since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
x
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Effective July 17, 2014, QLT Inc. (the Company or QLT) entered
into a letter agreement with Sukhi Jagpal, the Companys Chief Financial Officer, in which the Company, among other things, agreed to provide a cash retention bonus of CAD $100,000 to Mr. Jagpal provided that Mr. Jagpal remains an
active employee of the Company for the period from July 16, 2014 to the Payment Date (defined below).
The retention bonus is payable 90 days
following the closing of the previously announced merger of QLT Acquisition Corp., an indirect wholly-owned subsidiary of the Company (AcquireCo) with and into Auxilium Pharmaceuticals, Inc. (Auxilium), pursuant to that
Agreement and Plan of Merger (the Merger Agreement) among the Company, Auxilium, QLT Holding Corp., a wholly owned subsidiary of QLT, and AcquireCo (the Merger), or February 28, 2015, whichever is later, provided that if
the Merger Agreement is terminated by either Auxilium or the Company, the cash retention bonus is payable 30 days following the date the termination of the Merger Agreement is announced or February 28, 2015, whichever is later (the
Payment Date).
A copy of the letter agreement is attached hereto as Exhibit 10.75 and is incorporated herein by reference. The foregoing
description of the letter agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the letter agreement.
Item 8.01. Other Events
The information set forth in
Item 5.02 above is incorporated by reference into this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Pursuant to the rules and
regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:
|
|
|
Number
|
|
Description
|
|
|
10.75
|
|
Letter Agreement between the Company and Sukhi Jagpal effective as of July 17, 2014
|
No Offer or Solicitation
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to
purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention
of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information
In connection with the proposed Merger, the Company plans to file with the Securities and Exchange Commission (the SEC) a registration statement on
Form S-4 that will include the joint proxy statement/circular of Auxilium and QLT and also constitutes a prospectus of QLT. Auxilium and QLT plan to mail the joint proxy statement/circular to their respective stockholders. INVESTORS ARE URGED
TO READ THE JOINT PROXY STATEMENT/CIRCULAR WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. You will be able to obtain the joint proxy statement/circular, as well as other filings containing information about Auxilium and
QLT, free of charge, at the website maintained by the SEC at www.sec.gov and, in QLTs case, also on the System for Electronic Document Analysis Retrieval (SEDAR) website maintained by the Canadian Securities Administrators
(CSA) at www.sedar.com. QLT stockholders may also obtain these documents, free of charge, from QLTs website at www.qltinc.com under the heading Investors and then under the heading Proxy Circulars or upon
request directly to QLT to the attention of QLT Investor Relations, 887 Great Northern Way, Suite 250, Vancouver, British Columbia, Canada, V5T 4T5. Auxilium stockholders may also obtain these documents, free of charge,
from Auxiliums website (www.Auxilium.com) under the heading InvestorsSEC Filings or by directing a request to made to Auxiliums Secretary at Auxilium Pharmaceuticals, Inc., 640 Lee Road, Chesterbrook, PA 19087.
Participants in the Solicitation
The respective
directors and executive officers of QLT and Auxilium and other persons may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the joint proxy statement/circular. Information regarding QLT
directors and executive officers is available in its Annual Report on Form 10-K/A filed with the SEC and CSA by QLT on April 30, 2014, and information regarding Auxiliums directors and executive officers is available in its
definitive proxy statement filed with the SEC by Auxilium on April 10, 2014. These documents can be obtained free of charge from the sources indicated above. Other information regarding the interests of the participants in the proxy
solicitation will be included in the joint proxy statement/circular and other relevant materials to be filed with the SEC and the CSA when they become available.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
QLT INC.
|
|
|
By:
|
|
/s/ Sukhi Jagpal
|
Name:
|
|
Sukhi Jagpal
|
Title:
|
|
Chief Financial Officer
|
Date: July 23, 2014
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024